HeartSciences launches breakthrough ECG technology at Canadian Cardiovascular Congress

The MyoVista hsECG was created using Continuous Wavelet Transform mathematics and goes past conventional ECG technology with new metrics to identify repolarization abnormalities. This latest capacity enables physicians to identify diastolic disorder that is typically diagnosed using tissue Doppler echocardiography.

The MyoVista hsECG, incorporates all the abilities of the full featured 12-lead resting ECG plus new proprietary informatics that really help in discovering diastolic disorder. Using machine learning, MyoVista hsECG technology detected diastolic disorder with 88 percent sensitivity, and 87 percent specificity, inside a recent medical trial at Mount Sinai Hospital in New You are able to.*

“The MyoVista hsECG represents a thrilling breakthrough in ECG technology,” stated Mark Hilz, Ceo, HeartSciences. “We expect to presenting this breakthrough technology towards the Canadian market.”

The unit can also be available over the Eu, where it received the CE (Conformité Européenne) Mark approval captured. HeartSciences can also be while expanding distribution to Australia, the Middle East, South America and Asia-Off-shore.

Episona adds D2C model for male potency test using epigenetics

Fecundation – sperm cell entering in ovum

Twelve months after diagnostics startup Episona made its male potency testing package open to fertility clinics, the organization is adding an on-demand testing service for that consumer market, based on a news release.

Regardless of the on-demand nature from the service, physicians will still evaluate individuals online demands for Seed and can order the exam if appropriate.

Advertisement

Here’s the way the service works. Consumers can order a testing package on the internet and receive it within the mail within 3 to 5 working days. They offer a semen sample and send it to Episona’s CLIA-certified lab for review. Consumers and also the ordering physician get a two-part report online within three days by having an assessment from the patient’s risk for male factor infertility, based on the release.

Seed is really a next-generation sequencing test that identifies indications of DNA methylation in sperm because of aging, smoking, pollution along with other factors. For the way where this happens, the DNA modifications can impact fertility and embryo development.

Within an interview last year, Episona President and CEO Alan Horsager stated that Seed could be offered like a first-line diagnostic before couples invest in pricey fertility treatments. But associated with pension transfer diagnostics within this space, Horsager stated Episona’s test isn’t covered with insurance. Patients be forced to pay the $895 cost out-of-pocket, on the top from the usual battery of tests.

Photo: Getty Images

Correction: An early on form of this story incorrectly spelled the organization name, Episona. We regret the mistake.

Anpac Bio Surpasses 50,000 Situation Study Milestone ‘Liquid Biopsy Pioneer’ Serving Individual, Medical, Insurance & Corporate Customers

SACRAMENTO, Calif., March. 17, 2017 /PRNewswire/ — Dr. Chris Yu, Ceo of worldwide existence sciences corporation Anpac Bio-Medical Science Company, announced now the organization set a brand new, worldwide record, processing and reporting 50 plus,000 cases worldwide from the company’s proprietary, “Cancer Differentiation Analysis” (CDA) liquid biopsy tests.

Referred to as “game altering”, and finding the, “Breakthrough Innovation Award”, at World Nobel Prize Laureate Summit and named, “Most Promising Cancer Screening Company”, in the 2017 Global Precision Medicine Industry Awards, Anpac Bio’s CDA technology effectively reinvents early cancer screening and recognition.

By analyzing simple, standard, bloodstream tests, and applying Anpac Bio’s proprietary, multi-level, multi-parameter, diagnostic algorithms, Anpac Bio’s CDA technology identifies cancer with measurably-greater precision than most up to date, conventional screening methods. Also it achieves this with no dangerous negative effects in patients generating far less “false positives” at a price substantially less than traditional testing and generating results in a few minutes of sample submission.

Comprehensive research validity data in the 50,000+ cases processed up to now demonstrate CDA diagnostics consistently identify over 26+ cancers — having a sensitivity and specificity rate selection of 75%-90% — usually identifying the condition at its earliest stages.

The organization has filed over 200 CDA-related patent applications worldwide – 65+ issued presently and maintains operations in six sites, employing over 100 people globally.

“Since our organization launched in 2008, Anpac Bio has pioneered the ‘liquid biopsy’ space,” states Dr. Yu. “Our CDA technologies have been extensively tested, verified, and used daily by a large number of Asia’s best-respected and famous medical institutions. We’re also generating equally accurate and good results in the U . s . States. So that as these studies continues to be printed and presented before respected scientific organizations, like the American Society of Clinical Oncology (ASCO) and also the World Nobel Prize Laureate Summit, our CDA exams are in great demand. We are now processing CDA tests for people, health systems, insurance providers, educational facilities, and corporations. We are very proud our CDA devices have advanced past the laboratory, and therefore are processing real tests legitimate people – saving lives every single day. Only at that rate, we project to double our CDA cases worldwide and save a lot more resides in 2018!”

To learn more about Anpac Bio book: world wide web.AnpacBio.com.

View original quite happy with multimedia:http://world wide web.prnewswire.com/news-releases/anpac-bio-surpasses-50000-situation-study-milestone-liquid-biopsy-pioneer-serving-individual-medical-insurance–corporate-customers-300538549.html

SOURCE Anpac Bio-Medical Science Company

Related Links

http://world wide web.AnpacBio.com

Abbott Releases Proclaim DRG Dorsal Root Ganglion Stimulator for Chronic Discomfort


Abbott is releasing within the U.S. its Proclaim DRG neurostimulation system to battle chronic discomfort in patients with complex regional discomfort syndrome within their legs. The merchandise includes an implantable neuromodulator that energizes the dorsal root ganglion (DRG), an Ipad for programming the unit, as well as an ipod device touch for that patient charge of the unit. Inside a recent medical trial, dorsal root ganglion stimulation has proven markedly better outcomes over spinal-cord stimulation in lots of patients struggling with chronic discomfort within the lower extremities.

Bluetooth wireless connectivity can be used to alter the settings around the implant and also to control just how much stimulation it ought to administer. The program aboard the implant may also be updated wirelessly.

When compared with Abbott’s first generation DRG neurostimulator, the Axium, the brand new Proclaim DRG implant includes a greater battery existence, making it used continuously longer without substitute.

Being MR-conditional, patients using the Proclaim DRG implant can continue to receive magnetic resonance scans (as much as 1.5 Tesla), as lengthy as certain safeguards are taken.

“Both clinical and real life data have proven that DRG stimulation produces lengthy-term, significant discomfort relief for patients with complex regional discomfort syndromes – like individuals resulting after total knee arthroplasty, feet surgical procedures or hernia surgery,” in Abbott’s announcement said Timothy Deer, M.D., an interventional discomfort physician, president and ceo from the Spine and Nerve Center of the Virginias in Charleston, West Virginia, who studied the unit. “The capability to offer DRG stimulation around the Proclaim platform is an extremely exciting advancement for individuals people who treat patients using these debilitating conditions and wish to provide respite from hard-to-treat neuropathic conditions.”

Product page: Proclaim DRG Neurostimulator…

Via: Abbott…

Editors

At Medgadget, we set of the most recent medical technology news, interview leaders within the field, and file dispatches from medical occasions from around the globe.

Ria Health Launches Mobile Application in lowering Consuming (Interview)

A week ago we shared 12 new companies unveiling their innovative ideas at Health 2.0’s Launch! event this season. During the exhibit hall, a couple of more initial phase companies were also leveraging Health 2. to kickoff new programs and technologies. One of these simple was the state launch of Ria Health‘s mobile application solution to help individuals reduce their consuming through a mix of support from addiction specialists and daily progress tracking. The organization started testing the merchandise captured and, getting seen great initial outcomes, has become making we’ve got the technology open to consumers seeking a brand new method of reduce consuming.

Among the original clinical founders and today Chief Medical Officer of Ria Health, Dr. John Mendelson, is quoted as stating that, “Leading scientific study has developed effective and safe treating excessive drinking, however these treatments haven’t been adopted. Being an worldwide recognized addiction specialist and investigator my team and that i produced Ria Health to create these treatments to everybody.”

The announcement also highlighted adding Tom Nix, former consultant, towards the core Ria Health team as Ceo. While ongoing their objective of realizing an interesting member experience, Tom’s role may also concentrate on the growth and development of proper funnel partnerships within corporate HR, health systems, and also the physician community. Commenting about this chance for enterprise growth, Tom believes that, “Ria Health might help employers offer private, effective choose to their workers with measured outcomes which are positive and cost-effective along with a convenient program you can use within the comfort and privacy that belongs to them home.”  While at Health 2., Medgadget had an opportunity to interact with Tom to find out more.

Medgadget: Where did the concept behind Ria Health originate from?

Tom Nix, Ria Health Chief executive officer

Tom Nix: Our mind of technology, and my buddy, Bob Nix, spent nine years building among the greatest technology platforms in healthcare at athenahealth. While transitioning from that role, he discovered Dr. John Mendelson, who had been operating in the addiction space. Bob was convinced within the effectiveness of Dr. Mendelson’s work and also the numerous Food and drug administration studies that demonstrated the advantages of addiction-related education. Because he began searching to have an initial use situation, Bob started to consider the difficulties and impact of consuming. The Nation’s Institute on Excessive Drinking and Alcoholism estimates that about 34 million individuals the U . s . States are afflicted by Alcohol Consumption Disorder By having an chance to deal with what could effectively certainly be a chronic illness, he felt it might be an essential need that the new solution might be introduced to promote to deal with.

Medgadget: Do you know the challenges of traditional methods to managing consuming?

Tom: Solutions happen to be attempted before but they’re frequently standalone medical, social, or technology-driven approaches. Traditional treatment methods are typically rehab or Aa (AA). They are two great options, however they don’t always fit exactly what the individual needs. Residential rehab lasts 4 weeks which may be very disruptive to daily existence since you need to really focus and disconnect throughout this program. AA is really a strong alternative but you will find people we’ve spoken with who aren’t confident with the religious facet of that group or even the public situation they’re place in despite having the ability to be “anonymous.”

Today, only 4% of people battling with consuming go for these kinds of programs. Clearly we want another solution. More lately, using the development of digital health, application-only solutions will be in this mixture. However, by having an application-only method, you miss the chance to supply individuals with true, significant, objective measures while connecting all of them with an assistance network simultaneously.

Medgadget: Exactly what does Ria Health do differently?

Tom: At Ria Health, we combine all multiple of those elements into one solution including certified telemedicine coaches, drink tracking and breath analyzer data, along with a social capacity to interact having a personal support included in the process. To provide you with a bit more detail, our certified coaches use people to put together strategies, plans, and goals in lowering or stop consuming. Many people tend from physician support since it may be very costly. However, there’s evidence to exhibit that whenever a health care provider is engaged, individuals tackling consuming challenges are more inclined to be concerned a bit longer of your time than programs without it element. Used, we all do observe that telemedicine sessions are really extremely popular since, anecdotally, individuals are more prepared to be obvious within their problems and supply more detail regarding their needs once they feel like maintaining their privacy, dignity, and there’s no shame or stigma that could be associated with classical consuming programs.

Documenting the amount of drinks and recording breath analyzer data assistance to evaluate how people do with time and supply metrics for progress towards each member’s goals. Users can invite anybody, just like a family or friend, right into a private social networking to sign up within their journey towards controlling their consuming habit. The social capacity derives, partly from what AA was achieving once they started within the 1903s. Basically we possess the capacity to permit member-to-member socialization, we have to be cautious to understand if this sounds like something our people want or maybe focusing interactions between your member, their coach, as well as their private social networking is so far as we ought to go.

The mixture of all of these features leads to people dramatically reducing their consuming and sustaining their participation within the program with time. Today, we’ve 4 patents pending around our approach and procedures.

Medgadget: You mention tracking progress. Do users eventually finish this program or transition into using Ria in different ways because they achieve their objectives?

Tom: Most behavior change for individuals managing their consuming happens within 12 several weeks. Included in the initial increase, people define their success criteria. For other individuals available, the aim is frequently abstinence. Something to become obvious about here’s that at Ria Health, we’re not requesting abstinence. People ought to set their very own, personal objectives and goals which may be any place in the plethora of reducing to stopping consuming altogether. Members’ motivations to scale back on consuming also influence their set goals and will include slimming down, better sleep, and getting better relationships. All of these are negative effects of consuming less often and therefore are essential for the member to acknowledge when figuring out what they’re searching to get away from this program.

Many people hit their success criteria earlier than others but have the ability to possibilities to carry on maintaining that success or using the program even more beyond their initial goals. Therefore we have graduates who achieve their objectives and finish this program. We have people using Ria Health like a maintenance program after they achieve their set goals by ongoing to trace their activity and interesting within the social media area of the technology to help keep themselves accountable.

Medgadget: Ria Health is formally launching today for consumers.

Tom: We intentionally launched having a direct-to-consumer model which, to the enjoyable surprise, resulted in we could rapidly begin growing our member base and immediately begin helping a lot of people. We did this individually distinct, before official launch, captured in The month of january. The advantage of this tactic is the fact that our initial people happen to be supplying insights into the way they make use of the system which will help us boost the consumer experience to higher improve our technology. Instead of awaiting a Business to business pilot, this method permitted us to obtain data from users faster. Already, we’re seeing typically 30 interactions per member monthly and also have documented over 16,000 member interactions up to now by having an expectation of doubling that to in excess of 30,000 over the following thirty days. The quantity of data we’re mining and making use of to enhance we’ve got the technology is going to be far more than any competitor entering this space. Once we start to build out our enterprise relationships, we can sit lower with health systems and providers and show real, significant outcomes from actual people.

Medgadget: Out of your initial group of data, whoever else discovered your people and also have you started to realize any one of individuals outcomes you pointed out?

Tom: At this time, our membership is all about 60% ladies and 40% men by having an average chronilogical age of 45 years. What’s really exciting though is the fact that our initial cohort of test people decreased their drinking typically 60% within the first thirty days. I’m able to really demonstrate a graph in our consumption with time data from people of Ria Health [see below].  Coming up, we’re intending to show more data, leveraging our user data and existing financial savings analyses using their company consuming reduction programs, about how helping our people reduce consuming also generates an essential roi for employers along with other healthcare organizations who we’re excited to start dealing with to deal with this critical need.

4 months of progress achieved by Ria Health people. All customer information is averaged within this chart showing daily bloodstream alcohol concentration (BAC) when compared with baseline BAC measured at the beginning of this program. Raw member information is smoothed having a 7-day moving average, and every reason for the chart shows the typical across all people tomorrow.

Link: Ria Health…

As Express Scripts pays $3.6B for eviCore Healthcare, did Amazon . com result in the PBM blink?

Money bag icon on blackboard with hand

Express Scripts intends to covering out $3.6 billion to purchase eviCore Healthcare from several investors. It’s an offer which will see the organization liberate in the prescription medication benefits manager and expand in to the wider arena of medical benefit management for insurers, media reports noted.

EviCore Healthcare pre-approves scans along with other pricey tests for health plans covering 100 million people, based on Bloomberg. Obviously, there’s the flipside of saving health plans money, as Saurabh Jha, a radiologist using the Hospital in the College of Pennsylvania, noted on Twitter:

Pharmacy benefit managers, amongst other things, negotiate prices of covered drugs with pharma companies, use financial incentives to influence patients to reduce-cost generics and manage high-cost niche medications.

The offer might be a method for Express Scripts to safeguard itself from the intimidating competition Amazon . com could offer whether it would transfer to the PBM sector, as CNBC reported captured. However in an announcement from Express Scripts CEO Tim Wentworth, it was not obvious the move through the PBM was reply to Amazon . com, although he did suggest the offer would consolidate its power within the patient benefit management market.

“By further strengthening our independent model and creating numerous possibilities for growth, the purchase of eviCore will provide value for the clients, patients, providers, and shareholders,” he stated within the statement.

Meant for its medical benefits management business, eviCore acquired QPID Health this past year. The company, which functions like a subsidiary of eviCore, created a clinical decision support tool that actually works on the top of providers’ electronic permanent medical record systems. Its Q-Guide is made to be utilized before high-cost, high-volume surgical procedures to provide physicians an easy method to evaluate the requirement for a process using the patient’s risks.

The purchase is anticipated to shut through the finish of the year.

Photo: StockFinland, Getty Images

Endologix receives IDE approval for EVAS2 confirmatory study to evaluate Nellix endovascular aneurysm sealing system

Printed 09 October 2017

Endologix has gotten investigational device exemption (IDE) approval in the US Fda (Food and drug administration) to commence a confirmatory clinical study to judge the security and effectiveness from the Nellix endovascular aneurysm sealing system (EVAS) for that endovascular management of infrarenal abdominal aortic aneurysms.

The EVAS2 IDE Multicenter Safety and Effectiveness Confirmatory Study (“EVAS2”) will prospectively assess the refined Indications to be used (IFU) and also the Nellix Gen2 EVAS System.

The research qualifies to sign up as much as 90 primary patients, with one-year follow-up data needed for that Pre-market Approval Application (PMA).

The Nellix EVAS product is an endovascular abdominal aortic aneurysm (“AAA”) therapy made to seal the whole aneurysm. Nellix is the foremost and only EVAS product developed as a substitute treatment method of traditional EVAR devices.

John McDermott, Ceo for Endologix, stated, “We’re very happy to receive IDE approval from the FDA to begin this confirmatory study and expect to collaborating using the investigators to offer the objective of commencing enrollment through the finish of the year.

In line with the anticipated enrollment timeline, one-year follow-up period, and regulatory review process, we still estimate PMA approval in 2020.”

Endologix, Corporation. develops and manufactures non-invasive treating aortic disorders. The Business’s focus is endovascular stent grafts to treat abdominal aortic aneurysms (AAA). AAA is a weakening from the wall from the aorta, the biggest artery in your body, producing a balloon-like enlargement. Once AAA develops, it is constantly on the enlarge and, if not treated, becomes more and more prone to rupture.

Source: Company Pr Release

Boston Scientific Appoints Desiree Ralls-Morrison General Counsel and company Secretary

MARLBOROUGH, Mass., March. 4, 2017 /PRNewswire/ — Boston Scientific Corporation (New york stock exchange: BSX) today announced the appointment of Desiree Ralls-Morrison as senior v . p ., general counsel and company secretary. Ralls-Morrison will join Boston Scientific on November 30, 2017, as part of the manager committee, with responsibility for supplying a lawyer over the company’s global companies and processes, and overseeing the business’s global compliance function.

Ralls-Morrison will succeed Timothy Pratt, executive v . p ., general counsel and company secretary, who announced his intention to retire from the organization in April 2017.  

“Desiree is definitely an accomplished leader within the medical industry with deep knowledge of broad-varying legal matters and enterprise business strategy,” stated Mike Mahoney, chairman and ceo, Boston Scientific. “We expect to her contributions to Boston Scientific and also the company’s ongoing growth.”

Ralls-Morrison most lately held the function of senior v . p ., general counsel, corporate secretary, and mind from the global litigation, government matters and public policy organizations at Boehringer Ingelheim USA. Formerly, she was general counsel for that Manley & Manley consumer group, getting progressed through roles of growing responsibility including senior counsel, assistant general counsel, and v . p . of law for that women’s health, nutritionals and over-the-counter companies.

Earlier in her own career, Ralls-Morrison would be a senior attorney and assistant counsel at Merck & Co, Corporation., focusing largely on regulatory and defective products matters, and just before that, she held litigation roles in the lawyers of Kelley Drye & Warren LLP and Shipman & Goodmand LLP. She presently serves around the Danbury Hospital/New Milford Hospital Board of Company directors and also the Inner-City Foundation for Charitable organization and Education. Desiree earned her juris physician from Harvard School, and her bachelor of arts in financial aspects and political science from Wesleyan College.

About Boston Scientific 
Boston Scientific transforms lives through innovative medical solutions that improve the healthiness of patients all over the world. Like a global medical technology leader in excess of 35 years, we advance science for existence by supplying an extensive selection of high end solutions that address unmet patient needs and lower the price of healthcare. To learn more, visit www.bostonscientific.com and connect on Twitter and Facebook.

CONTACTS:

Kate Haranis
Media Relations
(508) 683-6585 (office)
[email protected] 

Susie Lisa, CFA
Investor Relations
(508) 683-5565 (office)
[email protected]

View original quite happy with multimedia:http://world wide web.prnewswire.com/news-releases/boston-scientific-appoints-desiree-ralls-morrison-general-counsel-and-corporate-secretary-300530536.html

SOURCE Boston Scientific Corporation

Related Links

http://world wide web.bostonscientific.com

Hologic Chief executive officer Steve MacMillan to Ring Nasdaq Opening Bell on October 2 to Start Cancer Of The Breast Awareness Month

MARLBOROUGH, Mass., Sept. 29, 2017 /PRNewswire/ — Hologic, Corporation. (Nasdaq: HOLX) announced today that Steve MacMillan, the business’s Chairman, President and Ceo, will join selected employees to ring the Nasdaq Opening Bell on October 2 with the oncoming of Cancer Of The Breast Awareness Month. Hologic is ringing the bell for that 12th consecutive year to celebrate the business’s recent advances in cancer of the breast screening and intervention, and also to underscore a continuing dedication to innovation in breast health.

Hologic is mainly centered on improving women’s health insurance and well-being through early recognition and treatment, and it is a recognised leader in cancer of the breast diagnosis. The Organization strives to build up solutions that better meet the requirements of clinicians as well as their patients.  In today’s healthcare landscape, these solutions must deliver improved patient satisfaction, better clinician workflow, and facility financial savings.

“Every year, we expect to Cancer Of The Breast Awareness Month being an chance to focus on our persistence for developing items that improve cancer of the breast recognition and address the unmet requirements of patients and providers in breast health,” stated MacMillan. “For instance, because we rang the Nasdaq bell last year, we’ve expanded the clinical brilliance claims in our market-leading Genius exam, and introduced numerous groundbreaking new screening and interventional products.”

Captured, the Genius 3D Mammography exam was authorized by the Food and drug administration as better than standard 2D mammography for routine cancer of the breast screening for ladies with dense breasts.[1],[2],[3],[4] This updated labeling took it’s origin from studies showing the exam improves invasive cancer of the breast recognition while reducing unnecessary recalls among women of breast densities, including individuals with dense breasts.  The expanded labeling offers clearness for physicians who formerly were unsure how you can screen patients with dense breasts.

Two recent product launches, the Brevera breast biopsy system with CorLumina imaging technology and also the SmartCurve breast stabilization system, are additional types of the milestones arrived at by Hologic previously year. The Brevera product is the earth’s first and just breast biopsy means to fix combine tissue acquisition, real-time imaging, sample verification and advanced publish-biopsy handling in a single, integrated system. The innovative system enables physicians to do fast and efficient procedures that save costs, enhance the patient experience, and enhance workflow within the biopsy suite.[5]

Hologic’s new SmartCurve system, when combined with the Genius exam, is the foremost and only 3D mammography system that’s proven to provide a far more comfortable and much more accurate mammogram, when compared with 2D mammography alone.[6] For a long time, ladies have reported staying away from annual mammograms due mainly towards the anxiety about discomfort connected with breast compression. With this thought, Hologic’s development and research team attempted to reduce breast discomfort without compromising picture quality, workflow or dose.[6] Inside a recent clinical study evaluating the SmartCurve breast stabilization system to traditional flat paddle compression, the SmartCurve system improved security in 93 percent of ladies who reported moderate to severe discomfort with standard compression.[5]

The Genius 3D Mammography™ exam (also referred to as the Genius™ exam) is just on a Hologic® 3D Mammography™ system. It includes a 2D and 3D™ image set, in which the 2D image could be either an acquired 2D image or perhaps a 2D image produced by the 3D™ image set. There are other than 4,000 Hologic 3D Mammography™ systems being used within the U.S. alone, so ladies have convenient accessibility Genius exam.  To understand more about the Genius exam, visit http://world wide web.Genius3DNearMe.com.

Webcast Information

Hologic’s participation within the Nasdaq opening bell ceremony is going to be aired live at https://new.livestream.com/NASDAQ/live with closed captioning around the Nasdaq MarketSite tower in Occasions Square.  A relevant video from the ceremony is going to be archived for just one year around the Nasdaq site.

About Hologic, Corporation.

Hologic, Corporation. is definitely an innovative medical technology company mainly centered on improving women’s health insurance and well-being through early recognition and treatment. For additional info on Hologic, visit world wide web.hologic.com.

Hologic, 3D, 3D Mammography, Brevera, CorLumina, Genius, SmartCurve and also the Science of Sure are trademarks and/or registered trademarks of Hologic, Corporation., and/or its subsidiaries in the U . s . States and/or any other countries.

Forward-Searching Statements

What is the news release could have forward-searching information which involves risks and uncertainties, including statements about using Hologic products. There might be no assurance these items will attain the benefits described herein or that such benefits is going to be replicated in almost any particular manner regarding a person patient, because the actual aftereffect of using these products are only able to be determined on the situation-by-situation basis. Additionally, there might be no assurance these products is going to be commercially effective or achieve any expected degree of sales. Hologic specifically disclaims any obligation or undertaking to produce openly any updates or revisions to the such statements presented herein to mirror any alternation in expectations or any alternation in occasions, conditions or conditions which such data or statements are based.

This post is not should have been an item solicitation or promotion where such activities are prohibited. For particular info on what products are for sale to purchase inside a particular country, please speak to a local Hologic salesman or email [email protected]

Media Contact:
Jane Mazur
508.263.8764 (direct)
585.355.5978 (mobile)
[email protected]

Investor Contact:
Michael Watts
858.410.8588
[email protected]

Emily Pan
Nasdaq
646.441.5120

Social Networking Contact:
Anna Gonzales
Nasdaq
646.944.5458

[1] Friedewald SM, Rafferty EA, Rose SL, et al. Cancer of the breast screening using tomosynthesis in conjunction with digital mammography. JAMA. 2014 Jun 25311(24):2499-507.

[2] Bernardi D, Macaskill P, Pellegrini M, et. al. Cancer of the breast screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography in contrast to 2D mammography alone (STORM-2): a population-based prospective study. Lancet Oncol. 2016 Aug17(8):1105-13.

[3] Is a result of Friedewald, SM, et al. “Cancer of the breast screening using tomosynthesis in conjunction with digital mammography.” JAMA 311.24 (2014): 2499-2507 a multi-site (13), non-randomized, historic control study of 454,000 screening mammograms investigating the first impact the development of the Hologic Selenia® Dimensions ® on screening outcomes. Individual results can vary. The research found a typical 41% (95% CI: 20-65%) increase which 1.2 (95% CI: .8-1.6) additional invasive breast cancers per 1000 screening exams put together in females receiving combined 2D FFDM and 3D™ mammograms acquired using the Hologic 3D Mammography™ System versus women receiving 2D FFDM mammograms only.

[4] U.S. Food & Drug Administration Premarket Approval (PMA).  Food and drug administration.gov https://world wide web.accessdata.food and drug administration.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P080003S005 accessed June 5, 2017.

[5] 3D biopsy only if combined with the Affirm breast biopsy system.

[6] Cruz, A. Improving Patient Security in Mammography. Hologic WordPress 00119 Rev 001 (2017).       

View original content:http://world wide web.prnewswire.com/news-releases/hologic-chief executive officer-steve-macmillan-to-ring-nasdaq-opening-bell-on-october-2-to-kick-off-breast-cancer-awareness-month-300527978.html

SOURCE Hologic, Corporation.

Related Links

http://world wide web.hologic.com

Kinova safeguards significant funding to purchase speeding up company growth and innovation

BOISBRIAND, QC, Sept. 28, 2017 /PRNewswire/ – Kinova ®, an artist and manufacturer of automatic solutions, has gotten funds totaling $25 million from four major contributors, including lead investor Fonds Manufacturier Québécois S.E.C. II co-investors KTB Network Co., Limited. (Columbia) and Foxconn (Taiwan) and BDC Capital, an investment arm of BDC (Canada).

“We would like our users to offer the remarkable with this robots — making more value on their own and society,Inch stated Kinova Chief executive officer Charles Deguire. “The financial support, broad expertise and geographic coverage in our experienced partners provides for us additional sources to accelerate our growth, rapidly and strategically establish our presence in untouched markets, develop a long type of breakthrough products, and propel our advanced manufacturing abilities.”

Partnering with investment advisory firm Keira Capital Partners Corporation., which helped Kinova facilitate the fundraiser process, the organization could solidify major Canadian and worldwide backing to assist it continue shaping an encouraging future. Each investor within this geographically diverse group brings some complementary experience essential to mentor Kinova’s growth.

“We are happy to be investing nowadays leader in human assistance robotics, and to achieve the chance to talk about our knowledge of business development and processes optimization. In so doing, we’ll have the ability to offer the company’s growth plans,” stated Jean Rochette and Marc Dufresne, partners at FMQ.

“We’re very impressed within the leadership and vision of Kinova in human collaboration robotics and therefore are proud to aid this kind of innovative company,” stated HoChan Lee, KTB Network’s md.

“Foxconn sees proper value dealing with Kinova and it is exploring collaborations in a variety of automatic fields,” based on an announcement in the Corporate Investment Division at Foxconn Technology Group/Hon Hai Precision Industry Co., Limited.

“We’re proud to aid Kinova, a very innovative Canadian company having a pursuit to provide existence-altering service robots to individuals. Our financial support will enable this youthful and dynamic team to carry on investments in development and research, all while enabling these to realize their ambitious growth plan,” stated Jean-Philippe Poissant, Director, Growth & Transition Capital at BDC Capital.

With each other, these significant funding contributions will enable Kinova — certainly one of Canada’s fastest-growing companies, as lately documented by Canadian Business‘s PROFIT 500 list — to help accelerate its development in three specific areas:

Research, development and product innovation

This investment allows Kinova to pursue and pioneer new advancements in the product range, further propelling a persons cause. Consequently, people will be presented better possibilities to complete remarkable feats beyond their very own limits.

A part of Kinova’s specific technique is to experience a number one role in medical robotics, that will include going after its mission to gain acceptance of recent technologies in additional conservative markets.

“We firmly think that our technology and expertise might help improve patient care,” Deguire stated. “We’re searching to construct partnerships with hospitals, governments along with other players in the market to ensure that our products lead towards the healing of patients.”

Sales, marketing and expansion

Conveying accounts for over 90% of Kinova’s business. To be able to better give you the world using its technologies, the following logical part of the business’s development would be to continue opening offices outdoors of Canada, particularly in Asia and the U . s . States, which becomes simpler to complete using these funds. Most lately, Kinova established a brand new office in Germany earlier in 2017.

Advanced manufacturing

With this particular new funding, Kinova expects to accelerate the study by itself production efficiency through digitization and robotization of their operations. The business’s intention would be to reduce its production costs, while growing both quality and timeliness of their output, taking “Factory 4.” to new heights.

About Kinova
Kinova is really a Canadian company that operates worldwide. Kinova designs and manufactures automatic solutions that are really simple to use, versatile and, most importantly, designed to increase human abilities through responsible, sincere purposes of technology. Kinova empowers people coping with upper-body mobility impairments to possess freedom of motion, professionals and universities they are driving their research forward, and health-care professionals to supply better outcomes for his or her patients.

About Fonds Manufacturier Québécois S.E.C. II
With more than $200 million in capital and sponsorship in the Caisse de dépôt et placement du Québec, Fonds Manufacturier Québécois helps Quebec’s manufacturing companies grow organically and thru acquisition to optimize their performance. FMQ combines the financial understanding of Caisse de dépôt using the operational skills of experienced managers. Thus, we provide assistance and knowledge of business development, operations management and financial management to Quebec’s manufacturing entrepreneurs to assist them to realize their projects. To learn more, please consult world wide web.fondsmanufacturier.com or visit our LinkedIn page.

About KTB Network Co., Limited.
KTB Network began almost 30 years ago because the first Investment Capital in Korea and it has been active venture investor in Korea, China, US and Canada. Throughout KTB’s over 35 many years of history, KTB has committed to over 3,000 startups in technology and healthcare sectors, which over 300 continued to list out on several stock markets, comprising over 10% of Korean IPOs. KTB Network also offers affiliated entities privately Equity, Asset Management and Investment Banking, serving the financial lending requirements of various stages of companies.

About Foxconn
Hon Hai Precision Industry Co., Limited. / Foxconn Technology Group and it is subsidiaries are mainly involved in the manufacture, sales and repair of connectors, situation, thermal module, wired/wireless communication products, optical products, power modules, and assemblies to be used within the IT, communications, automotive equipment, precision molding, automobile and electronic devices industries.

About BDC Capital
Using more than $2 billion under management, BDC Capital may be the investment arm of BDC, becoming a proper partner to Canada’s state-of-the-art and-potential firms. It provides a variety of equity, investment capital and versatile growth, and transition capital methods to help Canadian entrepreneurs scale their companies into global champions. For more information, visit bdc.ca/capital.

About Keira Capital Partners Corporation.
Keira Capital is really a registered independent exempt market securities dealer using the Autorité plusieurs Marchés Financiers of Quebec. Keira concentrates on the transactional problems with Canadian companies, both across the country and worldwide, with the aid of a group of innovative professionals, all whom have significant experience of business and financial transactions.

SOURCE Kinova Robotics

Related Links

http://world wide web.kinovarobotics.com/